MicrobiologyTier 1Medical Sciences concept

Post-transplant infection timeline (bacterial <1mo, viral/opportunistic 1-6mo, community-acquired >6mo)

Core concept

Post-transplant infection risk follows a predictable timeline driven by the dominant risk factor at each stage: surgical/nosocomial factors early, net immunosuppression intensity in the middle period, community exposure later -- matching timing to likely organism is the exam task
<1 month post-transplant: infections resemble those of any major surgery -- bacterial and fungal, related to the surgical wound, lines, catheters, anastomotic complications -- opportunistic infections are rare this early (immunosuppression hasn't yet had its full cumulative effect, and there's been no time for reactivation)
1-6 months: peak period for opportunistic and reactivation infections -- net immunosuppression is at its cumulative height, viral reactivation from latency occurs here

Period	Dominant infections
<1 month	Bacterial (surgical site, line, UTI), early fungal (Candida), donor-derived infection
1-6 months	CMV, EBV (PTLD risk), BK virus (renal), Pneumocystis jirovecii, Aspergillus, Listeria, TB reactivation -- classic opportunistic window
>6 months	Community-acquired infections (typical bacterial pneumonia, UTI) in patients with good graft function and reduced maintenance immunosuppression; ongoing opportunistic risk continues in patients with poor graft function/high chronic immunosuppression or chronic viral disease

Universal prophylaxis (e.g. PJP prophylaxis with cotrimoxazole, antiviral CMV prophylaxis) is specifically timed to cover the highest-risk 1-6 month window, and its withdrawal can unmask "late-onset" opportunistic infection shifted beyond the classic timeline

Trap: dismissing an opportunistic pathogen (e.g. PJP, CMV) as "unlikely" in a patient presenting more than 6 months post-transplant -- prophylaxis discontinuation, augmented immunosuppression for rejection treatment, or poor baseline graft function shifts risk later than the textbook timeline
A fever <1 month post-transplant is usually a surgical/nosocomial problem first -- work up the wound, lines, and anastomosis before broadening to an opportunistic infection screen
Augmented immunosuppression for rejection treatment (e.g. pulse steroids, T-cell depleting therapy) effectively "resets the clock", returning the patient to a 1-6-month-equivalent opportunistic infection risk regardless of actual time since transplant

CMV risk within this window links directly to CMV risk stratification (donor/recipient serostatus) - serostatus determines risk magnitude, this timeline determines expected timing
PTLD (EBV-driven) risk peaks in the same 1-6 month high-immunosuppression window, reflecting loss of T-cell surveillance over latent EBV
Same "net immunosuppression state determines infection risk more than time alone" principle applies when interpreting infection risk in any chronically immunosuppressed patient (e.g. biologic therapy for autoimmune disease), not just transplant recipients

3 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.